Carosyn (Carnosine)

Carnosine is a naturally occurring dipeptide composed of beta-alanine and L-histidine, concentrated in skeletal muscle and brain tissue. It exerts antioxidant and anti-glycation effects primarily by quenching reactive oxygen species and chelating metal ions that drive oxidative damage.

Origin & History

Carnosine (branded as Carosyn) is a naturally occurring dipeptide composed of β-alanine and L-histidine, with the chemical formula C₉H₁₄N₄O₃. Found primarily in human brain, muscle, and gastrointestinal tract tissues, it is typically produced synthetically or via enzymatic synthesis for commercial use rather than extracted from natural sources.

Historical & Cultural Context

No historical context or traditional medicine systems mentioning carnosine use are described in the available sources. As an endogenous compound discovered in modern times, it lacks traditional medicinal heritage.

Health Benefits

• Antioxidant properties - Evidence quality not specified in available research
• Geroprotective (anti-aging) effects - Evidence quality not specified in available research
• Antineoplastic (anti-cancer) potential - Evidence quality not specified in available research
• May support muscle and brain function due to high tissue concentrations - Theoretical based on tissue distribution
• Potential cellular health support - Mechanism details not provided in available research

How It Works

Carnosine scavenges reactive oxygen species (ROS) and reactive nitrogen species by donating protons to free radicals, effectively interrupting lipid peroxidation chain reactions. It chelates divalent metal ions such as copper and zinc, reducing metal-catalyzed oxidative stress, and inhibits advanced glycation end-product (AGE) formation by reacting with carbonyl groups on glucose-modified proteins in a process called transglycation. Additionally, carnosine modulates the proteasome pathway to facilitate clearance of damaged proteins, and its histidine moiety contributes pH-buffering capacity in contracting muscle tissue by acting as a proton acceptor.

Scientific Research

The available research dossier lacks details on key human clinical trials, RCTs, or meta-analyses for carnosine. No PubMed PMIDs, specific study designs, sample sizes, or clinical outcomes are provided in the current sources.

Clinical Summary

Human evidence for carnosine supplementation remains limited in quantity and study size, with most clinical trials involving fewer than 100 participants and short durations of 8–12 weeks. A double-blind trial in children with autism spectrum disorder (n=31) reported improvements in receptive vocabulary and behavior using 800 mg/day of carnosine, though replication is lacking. Animal and in vitro studies consistently demonstrate life-extension effects in model organisms and inhibition of tumor cell proliferation, but these findings have not been robustly translated to human RCTs. Overall, evidence quality is preliminary to moderate for antioxidant and muscle-buffering effects, and insufficient to draw firm conclusions on anti-cancer or strong geroprotective outcomes in humans.

Nutritional Profile

Carnosine (β-alanyl-L-histidine) is a naturally occurring dipeptide composed of β-alanine and L-histidine, with a molecular weight of 226.23 g/mol. It is not a traditional nutrient but a bioactive compound found endogenously in high concentrations in skeletal muscle (5–10 mmol/kg wet weight in type II fast-twitch fibers), cardiac muscle, and brain tissue. Key bioactive properties include: • Endogenous antioxidant — scavenges reactive oxygen species (ROS) including hydroxyl radicals, superoxide, and singlet oxygen; also chelates pro-oxidant transition metal ions (Cu²⁺, Zn²⁺, Fe²⁺) at physiologically relevant concentrations. • Anti-glycation agent — inhibits formation of advanced glycation end-products (AGEs) and advanced lipoxidation end-products (ALEs) by reacting with reactive carbonyl species (methylglyoxal, glyoxal, hydroxynonenal). • pH buffering capacity — contributes ~10–20% of intramuscular buffering capacity due to the imidazole ring of histidine (pKa ~6.83), relevant during high-intensity anaerobic exercise. • Anti-inflammatory modulator — may downregulate NF-κB signaling and reduce pro-inflammatory cytokine production (TNF-α, IL-6). Typical supplemental doses: 500–2000 mg/day of L-carnosine. Bioavailability considerations: Oral carnosine is rapidly hydrolyzed by serum carnosinase (CN1, encoded by CNDP1 gene) into β-alanine and L-histidine in human plasma, with a half-life of minutes in circulation. This limits systemic bioavailability of intact carnosine significantly; plasma carnosine levels after oral dosing are transient and low. Intramuscular carnosine loading is more effectively achieved via β-alanine supplementation (3.2–6.4 g/day over 4–10 weeks increases muscle carnosine by 40–80%). Contains no significant macronutrients (fat, carbohydrate, fiber), vitamins, or minerals per se. Each molecule provides approximately 1 mol β-alanine and 1 mol L-histidine upon hydrolysis. No caloric contribution at typical supplement doses.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are specified in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

β-alanine, L-histidine, antioxidants, cellular health compounds, muscle support nutrients

Safety & Interactions

Carnosine is generally well-tolerated at typical supplemental doses of 500–1000 mg/day, with no serious adverse events reported in short-term human trials. Mild gastrointestinal discomfort such as nausea has been noted anecdotally at higher doses. Carnosine may theoretically potentiate the effects of copper-chelating drugs or interact with medications sensitive to zinc bioavailability shifts, though no formal pharmacokinetic drug interaction studies exist. Safety data in pregnant or breastfeeding women is insufficient to establish a recommendation, and use during pregnancy should be avoided without medical supervision.